Table 4 Out-of-pocket and capitalized costs per approved drug for NMEs only
From: Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Drug Type | Phase | Expected out-of-pocket clinical costs (in millions 2013 USD) | Out-of-pocket clinical cost per approved drug (in millions 2013 USD) | Capitalized expected clinical costs (in millions 2013 USD) | Capitalized clinical cost per approved drug (in millions 2013 USD) |
|---|---|---|---|---|---|
Non-orphan | 1 | $2.81 | $340.30 | $5.16 | $488.88 |
2 | $7.00 | $11.11 | |||
3 | $25.75 | $34.82 | |||
Total | $35.56 | $51.09 | |||
Orphan | 1 | $4.27 | $137.12 | $9.61 | $242.46 |
2 | $20.86 | $39.87 | |||
3 | $20.02 | $30.35 | |||
Total | $45.15 | $79.83 |